Articles from Harrison.ai

Today, Harrison.ai submitted a Citizen Petition asking the Food and Drug Administration (FDA) to create a streamlined pathway to market for certain AI-powered radiology diagnostic devices. Under the new pathway, manufacturers that have already received 510(k) clearance could comply with robust post-market study requirements instead of submitting new 510(k)s for expanded capabilities. The proposed pathway would reduce delays and costs that restrict U.S. access to AI compared to other nations, with adequate controls to ensure continued safety and effectiveness. Harrison.ai shares the Administration’s interest in ensuring American patients benefit from AI advances in healthcare that are already available in the EU, Asia Pacific, and elsewhere around the world.

Harrison.ai, a global leader in clinical artificial intelligence, today announced it now holds three FDA Breakthrough Device Designations for CT imaging solutions, further solidifying its position at the forefront of next-generation AI for driving efficient, quality patient care.

Harrison.ai, a global leader in clinician-led imaging AI, today announced that Annalise.ai solutions will now be known as Harrison.ai Radiology. This marks an important milestone in unifying the company's mission under a single, strong and well-funded global brand. The new identity is reflected in the relaunched website at www.harrison.ai.

Harrison.ai, a leading healthtech company, today announced that its radiology-specific foundation model, Harrison.rad.1, delivered exceptional preliminary results in an independent, large-scale evaluation by Mass General Brigham (MGB) and the American College of Radiology.

Harrison.ai, a leading global healthtech company and developer of AI-powered medical diagnostic support and workflow solutions, announced today the accelerated expansion of its operations into the United States, a move supported by US$1​12​ million of Series C funding. The funding will also fuel the company’s product roadmap and continued growth in the UK, EMEA and APAC. The round is one of the largest capital raises in the medical AI space over the past twelve months.